ArticleAAPS PharmSciTech2025
Nano-Based Hydrogel for Cutaneous Sesamol Delivery in UVB-Induced Skin Injury.
Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Licuri Oil (Molecules (Basel, Switzerland) · 2026Article
- A comprehensive review on the anti-cancer properties of sesame lignans: chemical composition, molecular mechanisms and prospects.RSC advances · 2025Review
- Repeated Administration of Guar Gum Hydrogel Containing Sesamol-Loaded Nanocapsules Reduced Skin Inflammation in Mice in an Irritant Contact Dermatitis Model.Pharmaceutics · 2025Article
- Neomycin sulfate and triamcinolone acetonide suspended ointment designed for transdermal delivery: formulation and in vitro evaluation.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dexamethasone, a glucocorticoid, is used to mitigate UVB radiation-induced skin inflammation. Nevertheless, its continuous use has been linked to adverse effects. Sesamol, a compound with promising pharmacological properties, faces a challenge due to its rapid skin permeation, which limits its effectiveness when administered cutaneously. Consequently, polymeric nanocapsules have emerged as a technological solution to enhance the skin residence time and efficacy of sesamol in topical applications. This study details the preparation of sesamol-loaded ethylcellulose nanocapsule suspensions and evaluates their in vitro cytotoxicity against keratinocyte and fibroblast cell lines using the MTT assay. The results show that while free sesamol reduced the viability of 3T3 fibroblast cells, this cytotoxic effect was mitigated upon nanoencapsulation. In HaCaT cells, only the highest concentration of nanoencapsulated sesamol exhibited a moderate cytotoxic effect. A nano-based hydrogel containing 1 mg/g of sesamol and 2.5% guar gum was formulated for cutaneous application. The hydrogel's pharmacological efficacy was assessed in an in vivo sunburn model induced by UVB light in Swiss mice, demonstrating that the sesamol-loaded nanocapsules significantly attenuated inflammatory responses, as evidenced by a reduction in ear thickness and polymorphonuclear cell infiltration. Furthermore, ex vivo permeation studies on UVB radiation-injured human skin confirmed that nanoencapsulation markedly reduced the permeation rate of sesamol through the skin's layers. The hydrogels were also found to be bioadhesive to human skin. In conclusion, the hydrogel containing sesamol-loaded nanocapsules presents a promising therapeutic approach for treating inflammatory skin conditions, including sunburn.
Indexed as
Identifiers
40045094What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.